Aktis Oncology (NASDAQ:AKTS) Coverage Initiated at TD Cowen

Stock analysts at TD Cowen began coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The brokerage set a “buy” rating on the technology company’s stock.

Separately, Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $31.67.

Aktis Oncology Trading Down 4.7%

Shares of NASDAQ AKTS opened at $19.92 on Tuesday. Aktis Oncology has a fifty-two week low of $18.02 and a fifty-two week high of $29.16.

Insider Activity

In other news, major shareholder Ansbert Gadicke acquired 1,112,777 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The stock was bought at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the transaction, the insider directly owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This represents a 12.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the acquisition, the insider owned 10,260,064 shares of the company’s stock, valued at $184,681,152. This represents a 12.17% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 6,117,776 shares of company stock worth $110,119,968. 3.30% of the stock is currently owned by insiders.

Key Headlines Impacting Aktis Oncology

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Bank of America initiated coverage with a “buy” rating and a $34.00 price target (implies ~71% upside vs. the referenced price), providing a sizeable bullish catalyst for AKTS.
• Positive Sentiment: Leerink Partners started coverage with an “outperform” rating and a $31.00 target (roughly 56% upside), adding another institutional endorsement that could attract investor interest. Article Title
• Positive Sentiment: JPMorgan initiated with an “overweight” rating and a $30.00 price target (~51% upside), adding further sell‑side conviction that AKTS’s pipeline and platform could support higher valuations. Article Title
• Positive Sentiment: TD Cowen (covered in TipRanks and The Fly writeups) initiated coverage with a Buy rating and highlighted Aktis’s differentiated miniprotein radiopharma platform and multi‑billion dollar sales potential — a thematic, research‑driven positive for investor sentiment. Article Title Article Title
• Neutral Sentiment: A short‑interest report in the record shows essentially zero reported short interest (entries list 0 shares and an uninformative NaN change), so short covering or aggressive short selling does not appear to explain today’s move.
• Negative Sentiment: Despite the bullish analyst initiations, the stock is trading down on the day with volume slightly below its average — a sign of short‑term profit taking or sector/market weakness outweighing the positive analyst news in the near term.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.